PDF(Pubmed)
Abstract：
UNASSIGNED: There are limited data to assess pharmacodynamic (PD) profiles of patients with STEMI undergoing primary percutaneous coronary intervention (PCI) and receiving cangrelor after pretreatment with ticagrelor.
UNASSIGNED: The PharmacOdynaMic effects of cangrelor in PatiEnts wIth acute or chronIc coronary syndrome undergoing percutaneous coronary intervention (POMPEII) registry (NCT04790032) is a prospective study conducted at Federico II University of Naples enrolling all patients undergoing PCI receiving cangrelor at operator\'s discretion. PD assessments were performed with 3 assays: (1) the gold standard light transmittance aggregometry (LTA) (20- and 5-μM adenosine diphosphate [ADP] stimuli); (2) VerifyNow P2Y12-test; (3) Multiplate electrode aggregometry (MEA), ADP-test.
UNASSIGNED: We analyzed 13 STEMI patients pretreated with ticagrelor within 1 h at the time they underwent primary PCI receiving cangrelor. All patients showed low maximal platelet aggregation at 30-minute during cangrelor infusion, as well as at 3 h and 4-6 h (corresponding to 1 h and 2-4 h after stopping cangrelor infusion) with no cases of high residual platelet reactivity. These results were consistent with all assays.
UNASSIGNED: PD data show that in contemporary real-world STEMI patients pretreated within 1 h with ticagrelor undergoing primary PCI, adding cangrelor resulted in fast and potent platelet inhibition, thus suggesting that cangrelor may bridge the gap until ticagrelor reaches its effect.
UNASSIGNED: The PharmacOdynaMic effects of cangrelor in PatiEnts wIth acute or chronIc coronary syndrome undergoing percutaneous coronary intervention (POMPEII) registry (NCT04790032) is a prospective study conducted at Federico II University of Naples enrolling all patients undergoing PCI receiving cangrelor at operator\'s discretion. PD assessments were performed with 3 assays: (1) the gold standard light transmittance aggregometry (LTA) (20- and 5-μM adenosine diphosphate [ADP] stimuli); (2) VerifyNow P2Y12-test; (3) Multiplate electrode aggregometry (MEA), ADP-test.
UNASSIGNED: We analyzed 13 STEMI patients pretreated with ticagrelor within 1 h at the time they underwent primary PCI receiving cangrelor. All patients showed low maximal platelet aggregation at 30-minute during cangrelor infusion, as well as at 3 h and 4-6 h (corresponding to 1 h and 2-4 h after stopping cangrelor infusion) with no cases of high residual platelet reactivity. These results were consistent with all assays.
UNASSIGNED: PD data show that in contemporary real-world STEMI patients pretreated within 1 h with ticagrelor undergoing primary PCI, adding cangrelor resulted in fast and potent platelet inhibition, thus suggesting that cangrelor may bridge the gap until ticagrelor reaches its effect.
摘要：
■评估接受直接经皮冠状动脉介入治疗(PCI)并在替格瑞洛预处理后接受坎格雷洛治疗的STEMI患者的药效学(PD)特征的数据有限。
■在接受经皮冠状动脉介入治疗（POMPEII）注册的急性或慢性冠状动脉综合征的Patients中，cangrelor的药物OdynaMic效应（NCT04790032）是在那不勒斯费德里科第二大学进行的一项前瞻性研究，招募所有接受PCI的患者。使用3种测定法进行PD评估：（1）金标准透光率聚集测定法（LTA）（20和5μM二磷酸腺苷[ADP]刺激）；（2）VerifyNowP2Y12测试；（3）多电极聚集测定法（MEA），ADP测试。
■我们分析了13例接受替格瑞洛的STEMI患者在接受cangrelor的原发性PCI治疗后1小时内接受替格瑞洛治疗。所有患者在注射坎格瑞洛期间30分钟时表现出低的最大血小板聚集，以及在3小时和4-6小时（对应于1小时和2-4小时后停止坎格瑞洛输注），没有高残余血小板反应性的病例。这些结果与所有测定一致。
■PD数据显示，在接受替格瑞洛初级PCI的1小时内接受预处理的当代真实世界STEMI患者中，添加坎格雷洛可导致快速有效的血小板抑制，因此表明坎格雷洛可能会弥合这一差距，直到替格瑞洛达到效果。
■在接受经皮冠状动脉介入治疗（POMPEII）注册的急性或慢性冠状动脉综合征的Patients中，cangrelor的药物OdynaMic效应（NCT04790032）是在那不勒斯费德里科第二大学进行的一项前瞻性研究，招募所有接受PCI的患者。使用3种测定法进行PD评估：（1）金标准透光率聚集测定法（LTA）（20和5μM二磷酸腺苷[ADP]刺激）；（2）VerifyNowP2Y12测试；（3）多电极聚集测定法（MEA），ADP测试。
■我们分析了13例接受替格瑞洛的STEMI患者在接受cangrelor的原发性PCI治疗后1小时内接受替格瑞洛治疗。所有患者在注射坎格瑞洛期间30分钟时表现出低的最大血小板聚集，以及在3小时和4-6小时（对应于1小时和2-4小时后停止坎格瑞洛输注），没有高残余血小板反应性的病例。这些结果与所有测定一致。
■PD数据显示，在接受替格瑞洛初级PCI的1小时内接受预处理的当代真实世界STEMI患者中，添加坎格雷洛可导致快速有效的血小板抑制，因此表明坎格雷洛可能会弥合这一差距，直到替格瑞洛达到效果。
